AKBA
NASDAQAkebia Therapeutics Inc.
Price$0.67-0.02 (-2.81%)
01:30 PM07:45 PM
News · 26 weeks39+33%
2026-04-192026-10-11
Mix1690d
- Other8(50%)
- SEC Filings4(25%)
- Earnings2(13%)
- Analyst1(6%)
- Insider1(6%)
Latest news
25 items- SECSEC Form 8-K filed by Akebia Therapeutics Inc.8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
- PRAkebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumWALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. During meetings, management will discuss its commercial products and clinical stage, differentiated pipeline assets for rare kidney diseases. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integr
- PRAkebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026. U.S. Renal Care will present the results of the VOICE trial evaluating the safety of three-times-weekly vadadustat compared with an erythropoiesis-stimulating agent (ESA) in patients receiving in-center hemodialysis as a late-breaking presentation. Additionally, Akebia will have multiple poster presentations featuring its rare
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the
- PRAkebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesOpen-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). Ebribafusp is an investigational, next-generation anti-C3d factor H fusion protein designed
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the
- PRAkebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in BostonCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026. During meetings, management will discuss its commercial products and its robust pipeline of clinical stage kidney disease programs. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company wit
- INSIDERCEO and President Butler John P. exercised 350,000 shares at a strike of $0.63, increasing direct ownership by 10% to 3,718,564 units (SEC Form 4)4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- ANALYSTAkebia Therapeutics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Akebia Therapeutics from Outperform to Market Perform and set a new price target of $1.00
- SECSEC Form S-8 filed by Akebia Therapeutics Inc.S-8 - Akebia Therapeutics, Inc. (0001517022) (Filer)
- SECSEC Form 10-Q filed by Akebia Therapeutics Inc.10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
- SECAkebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
- PRAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsQ2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; initial data expected in 2027 Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical compan
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly-hired employees options to purchase an aggregate of 61,000 shares of Akebia’s common stock on July 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.32 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the s
- PRAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney DiseasesCAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). Ebribafusp (previously referred to as AKB-097 and ADX-097) is an anti-C3d factor H fusion protein designed to inhibit complement activation in tissues without inhibiting the complement system in the blood. "There are over 200,
- PRAkebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business HighlightsCAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026, following the close of the financial markets. Akebia will host a conference call on Wednesday, August 5, 2026, at 4:30 p.m. EDT to discuss its financial results and recent business highlights. To access the call, please dial (646) 307-1963 or toll-free (800) 715-9871 and enter passcode: 4727037. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the conference call wi
- PRAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia’s common stock on June 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.14 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the s
- INSIDERSVP, CFO, CBO & Treasurer Ostrowski Erik sold $62,181 worth of shares (56,019 units at $1.11), decreasing direct ownership by 8% to 616,616 units (SEC Form 4) to satisfy withholding tax4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- SECAkebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
- PRU.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESAVafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people imp
- INSIDERDirector Wolf Myles was granted 35,700 shares, increasing direct ownership by 27% to 169,081 units (SEC Form 4)4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- INSIDERDirector Smith Cynthia was granted 35,700 shares, increasing direct ownership by 22% to 196,633 units (SEC Form 4)4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- INSIDERDirector Rogers Michael W was granted 35,700 shares, increasing direct ownership by 22% to 197,429 units (SEC Form 4)4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- INSIDERDirector Frieson Ron was granted 35,700 shares, increasing direct ownership by 28% to 165,200 units (SEC Form 4)4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
- SECAkebia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
AKBA FAQ
7 questionsWhat does Akebia Therapeutics Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in...Where does AKBA stock trade?
Akebia Therapeutics Inc. (AKBA) is listed on NASDAQ.What sector and industry is AKBA in?
Akebia Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Akebia Therapeutics Inc. go public?
Akebia Therapeutics Inc. (AKBA) completed its IPO in 2014.What are analysts saying about AKBA?
Akebia Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $100.00 price target on 2026-08-07.What companies are similar to AKBA?
Notable peers in the same industry include ISEE (IVERIC bio Inc.), FGEN (FibroGen Inc), ARDX (Ardelyx Inc.), KDNY (Chinook Therapeutics Inc.), TCDA (Tricida Inc.). Compare AKBA side-by-side with any of them on Quantisnow.How can I track AKBA on Quantisnow?
Quantisnow aggregates Akebia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKBA to receive live email and push alerts on every new disclosure.